 BALTIMORE-- BUSINESS WIRE --MyMD Pharmaceuticals, Inc. Nasdaq: MYMD MyMD or the Company, a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases, is presenting data today at the 2022 British Society for Immunology BSI Congress in Liverpool, England. Results from preclinical and clinical studies showed that MYMD-1 was safe and well-tolerated in healthy subjects and significantly reduced inflammation in a mouse model compared to the widely used arthritis treatment etanercept Enbrel. These findings support the continued evaluation of MYMD-1 for autoimmune and inflammatory disorders. 